Skip to content

Studying the effect of N-acetyl cysteine in cirrosis

Studying the effect of N-acetyl cysteine in cirrhotic patients

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190528043734N1
Enrollment
80
Registered
2019-09-06
Start date
2019-09-11
Completion date
Unknown
Last updated
2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cirrhosis. Cirrhosis

Interventions

Intervention 1: Intervention group: patients will receive 600 mg tablets of NAC twice a day for 6 months. Intervention 2: Control group: Patients will receive placebo tablets completely similar to NAC

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Child suffering class A or B of cirrhosis Patients with score of 5-9 of child pugh score

Exclusion criteria

Exclusion criteria: Patient with class c of child pugh score

Design outcomes

Primary

MeasureTime frame
Liver function. Timepoint: At the baseline and 6 months after starting N-acetylcycteine. Method of measurement: Child-Puff score system with scores categorized as A, B and C.;Liver function. Timepoint: At the baseline and 6 months after starting N-acetylcycteine. Method of measurement: MELD scoring system based on bilirubin and creatinine serum levels.

Secondary

MeasureTime frame
Kidney function. Timepoint: At the baseline and 6 months after starting N-acetylcycteine. Method of measurement: Creatinine level due to lab results.;Kidney function. Timepoint: At the baseline and 6 months after starting N-acetylcycteine. Method of measurement: Urea level due to lab results.;Liver function. Timepoint: At the baseline and 6 months after starting N-acetylcycteine. Method of measurement: Aspartate Transaminase (AST) level due to lab results.;Liver function. Timepoint: At the baseline and 6 months after starting N-acetylcycteine. Method of measurement: Alanine Aminotransferase (ALT) level due to lab results.;Liver function. Timepoint: At the baseline and 6 months after starting N-acetylcycteine. Method of measurement: Total bilirubin level due to lab results.;Liver function. Timepoint: At the baseline and 6 months after starting N-acetylcycteine. Method of measurement: Albumin level due to lab results.;Liver function. Timepoint: At the baseline and 6 months after starting N-acetylcycteine. Method of measurement: Prothrombin time (PT) level due to lab resulst.;Liver function. Timepoint: At the baseline and 6 months after starting N-acetylcycteine. Method of measurement: International Normalized Ratio (INR) level due to lab resulst.;Blood parameter. Timepoint: At the baseline and 6 months after starting N-acetylcycteine. Method of measurement: Hemoglobin level due to lab results.;Blood parameter. Timepoint: At the baseline and 6 months after starting N-acetylcycteine. Method of measurement: Platelet number due to lab results.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Masoumi

Shahid Beheshti University of Medical Sciences

maryammasoumii666@gmail.com+98 21 2243 9770

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026